Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Key Stats

• Today's Range: $1.64 to $1.81
• 50-Day Range: $1.47 to $2.02
• 52-Week Range: $0.73 to $5.23
• Volume: 38,185 shs
• Average Volume: 81,919 shs
• Market Capitalization: $42.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Moderate Buy

Accelerate Diagnostics Stock Analysis - MarketRank™

Accelerate Diagnostics scored higher than 49% of companies evaluated by MarketBeat, and ranked 613th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Accelerate Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Accelerate Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Accelerate Diagnostics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accelerate Diagnostics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.48% of the float of Accelerate Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Accelerate Diagnostics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Accelerate Diagnostics has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accelerate Diagnostics does not currently pay a dividend.

Dividend Growth

Accelerate Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.62

Percentage of Shares Shorted

3.48% of the float of Accelerate Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Accelerate Diagnostics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Accelerate Diagnostics has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: -0.60

News Sentiment

Accelerate Diagnostics has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Accelerate Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

AXDX Stock Analysis - Frequently Asked Questions

How have AXDX shares performed this year?

Accelerate Diagnostics' stock was trading at $3.92 at the beginning of the year. Since then, AXDX shares have decreased by 56.6% and is now trading at $1.70.
View the best growth stocks for 2024 here.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its earnings results on Tuesday, November, 9th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.50) by $2.00. The medical research company earned $3.12 million during the quarter, compared to analysts' expectations of $3.51 million.

When did Accelerate Diagnostics' stock split?

Accelerate Diagnostics shares reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' top institutional investors include Griffin Asset Management Inc. (5.65%), Geode Capital Management LLC (0.51%), Y Intercept Hong Kong Ltd (0.08%) and Wolverine Asset Management LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience, Steven Reichling, Ron Price, Hany Massarany and Jack W Schuler.
View institutional ownership trends.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AXDX
• CUSIP: N/A
• CIK: 727207
• Web: acceleratediagnostics.com
• Phone: (520) 365-3100
• Fax: 520-269-6580
• Employees: 134
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.00
• High Stock Price Target: $1.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: -41.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-61,620,000.00
• Net Margins: -471.83%
• Pretax Margin: -444.14%
• Return on Equity: N/A
• Return on Assets: -191.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $12.06 million
• Price / Sales: 3.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: -1.24

Miscellaneous

• Outstanding Shares: 25,040,000
• Free Float: 14,125,000
• Market Cap: $42.57 million
• Optionable: Optionable
• Beta: 0.59